国产培美曲塞治疗晚期非小细胞肺癌的疗效及不良反应观察  

Observation of Clinical Efficacy and Adverse Drug Reactions of Domestic Pemetrexed in the Treatment of Non-small Cell Lung Cancer

作　　者：孙立伟[1] 孙志明[1] 吴剑涓[2] 

机构地区：[1]天津市环湖医院十三病区,天津300060 [2]天津市环湖医院临床药学室,天津300060

出　　处：《中国药房》2012年第42期3992-3994,共3页China Pharmacy

摘　　要：目的:观察国产培美曲塞治疗晚期非小细胞肺癌的疗效及不良反应。方法:回顾性分析我院收治的62例晚期非小细胞肺癌患者,按照使用培美曲塞种类的不同分为2组,A组使用国产培美曲塞,B组使用进口培美曲塞,比较2组用药1年后的疗效及不良反应。结果:2组用药1年后的疗效及不良反应差异均无统计学意义(P>0.05)。结论:国产培美曲塞用于晚期非小细胞肺癌治疗1年后的疗效及不良反应与进口培美曲塞相近。OBJECTIVE： To observe clinical efficacy and adverse drug reactions of domestic pemetrexed in the treatment of non-small cell lung cancer （NSCLC）. METHODS： 62 patients with advanced NSCLC admitted in our hospital were analyzed retro- spectively, and they were divided into 2 groups according to different kinds of pemetrexed. Group A was given domestic peme- trexed, group B was given imported pemetrexed. Therapeutic efficacy and adverse drug reactions were compared between 2 groups after 1 year of treatment. RESULTS： After 1 year, therapeutic efficacy and adverse drug reactions of 2 groups had no significant differences （P〉0.05）. CONCLUSION： Clinical efficacy and adverse drug reactions of domestic pemetrexed are similar to imported pemetrexed for NSCLC 1 year later.

关 键 词：培美曲塞 非小细胞肺癌 疗效 不良反应 

分 类 号：R979.1[医药卫生—药品] R969.4[医药卫生—药学]